[1]Bosch J, Iwakiri Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models. Hepatol Int, 2018,12(Suppl 1):1-10.
[2]Abraldes JG, Sarlieve P, Tandon P. Measurement of portal pressure. Clin Liver Dis, 2014,18(4):779-792.
[3]Khanna R, Sarin SK. Non-cirrhotic portal hypertension. J Hepatol, 2014, 60:421-441.
[4]李晓珂, 薛舒文, 杨新乐,等. 非肝硬化性门静脉高压症的研究现状. 临床肝胆病杂志, 2020,36(11):2565-2568.
[5]Siramolpiwat S, Seijo S, Miquel R, et al. Idiopathic portal hypertension: natural history and long-term outcome. Hepatology, 2014,59:2276-2285.
[6]刘海博, 张博静, 吕勇,等. 特发性非肝硬化门静脉高压症的研究进展. 临床肝胆病杂志, 2017, 33(2):348-353.
[7]Schouten JNL, Nevens F, Hansen B, et al. Idiopathic noncirrhotic portal hypertensionis associated with poor survival: results of a long-term cohort study.Aliment Pharmacol Ther, 2012,35(12):1424-1433.
[8]Vispo E, Moreno A, Maida I, et al. Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. AIDS, 2010,24:1171-1176.
[9]Schouten JN, Van der Ende ME, Koeter T, et al. Risk factors and outcome of HIV-associatedidiopathic noncirrhotic portal hypertension. Aliment Pharmacol Ther,2012,36(9):875-885.
[10] Franchi-Abella S, Fabre M, Mselati E, et al. Obliterative portal venopathy: astudy of 48 children. J Pediatr, 2014,165(1):190-193,e202.
[11] Sood V, Lal BB, Khanna R, et al. Noncirrhotic portal fibrosis in pediatric population.J Pediatr Gastroenterol Nutr, 2017,64(5):748-753.
[12] Sato Y, Ren XS, Harada K, et al. Induction of elastin expression in vascular endothelial cells relates to hepatoportal sclerosis in idiopathic portal hypertension:possible link to serum anti-endothelial cell antibodies. Clin Exp Immunol,2012,167(3):532-542.
[13] Pulvirenti F, Pentassuglio I, Milito C, et al. Idiopathic non cirrhotic portal hypertension and spleno-portal axis abnormalities in patients with severe primary antibody deficiencies. J Immunol Res, 2014,2014:672458.
[14] Koot BG, Alders M, Verheij J, et al. A de novo mutation in KCNN3 associated with autosomal dominant idiopathic non-cirrhotic portal hypertension.J Hepatol, 2016,64(4):974-977.
[15] Sarin SK, Kumar A, Chawla YK, et al. Noncirrhotic portal fibrosis/idiopathic portalhypertension: APASL recommendations for diagnosis and treatment. Hepatol Int, 2007,1:398-413.
[16] Nakanuma Y, Tsuneyama K, Ohbu M, et al. Pathology and pathogenesis of idiopathic portal hypertension with an emphasis on the liver. Pathol Res Pract, 2001, 197(2):65-76.
[17] Cazals-Hatem D, Hillaire S, Rudler M, et al. Obliterative portal venopathy: portal hypertension is not always present at diagnosis. J Hepatol, 2011, 54(3):455-461. |
